Your Gut Bacteria May Explain Why Semaglutide Reduces Alcohol Cravings

If you have ever wondered why quitting alcohol feels like fighting your own body as much as your own willpower, a new review points at an unexpected co-conspirator: the trillions of bacteria living in your gut. Researchers pooled findings from eleven clinical trials testing whether repairing gut bacteria, or hijacking the hormones gut bacteria help regulate, can ease alcohol use disorder (AUD) and the liver damage that often comes with it. The results are early and mixed, but one detail is likely to grab attention: several trials of GLP-1 drugs, the same drug class behind Ozempic and Wegovy, cut heavy drinking days in adults with AUD.

Key takeaways:

• A systematic review of 11 small clinical trials (779 participants total) found that fecal transplants, prebiotic fiber, probiotics, and GLP-1 drugs like semaglutide produced measurable, if inconsistent, improvements in alcohol craving, drinking, and liver markers in people with alcohol use disorder.
• The most consistent single result: 3 of 5 GLP-1 receptor agonist trials (two semaglutide trials and one dulaglutide trial) showed a statistically significant reduction in drinking; the other 2 moved in the same direction but did not reach statistical significance.
• A one-time fecal microbiota transplant reduced alcohol craving and serious AUD-related complications within weeks in a small trial of men with cirrhosis.
• The headline caveat: every trial was small (16 to 151 people), several results were not statistically significant, and this is a review of existing small studies, not one large new trial.

Gut-Brain Axis Therapies Show Early Signals in Alcohol Use Disorder

A systematic review published in Metabolism Open found that treatments aimed at the gut-brain axis (the two-way signaling network connecting gut bacteria to brain function through nerves, hormones, and immune messengers) produced measurable, though inconsistent, benefits across eleven clinical trials of adults with alcohol use disorder (AUD). Five of those eleven trials specifically identified gut dysbiosis (an imbalance in the normal mix of gut bacteria) as a common feature in people with AUD, supporting the idea that gut and brain problems in alcohol use disorder are connected rather than separate. In the most directly gut-targeted trial, a one-time fecal microbiota transplant (FMT, transferring stool bacteria from a screened healthy donor into a patient's colon) given to men with alcohol-related cirrhosis led to craving reduction in 9 of 10 FMT recipients versus 3 of 10 on placebo by day 15 (p = 0.02), and alcohol-related serious complications were far less common in the FMT group over follow-up (1 event versus 7, p = 0.02).

Alcohol-Associated Liver Disease Patients Have the Most at Stake

People managing alcohol use disorder alongside alcohol-associated liver disease (ALD) or alcohol-associated hepatitis (AAH, liver inflammation caused by heavy drinking) are the group this research speaks to most directly, since three of the eleven trials enrolled ALD or AAH patients specifically. Existing drugs for AUD, such as naltrexone, acamprosate, and disulfiram, have only modest efficacy, and relapse rates after treatment exceed 60 percent, which is part of why researchers are looking at the gut as a new lever. In one retrospective cohort of 61 men with severe alcoholic hepatitis, those who received FMT had a lower relapse rate than corticosteroid responders receiving standard care (28.6% versus 53.8%, p = 0.04) and went roughly twice as long before relapsing (a median of 436 days versus 197 days, p = 0.002), though three-year survival was only marginally higher in the FMT group (65.7%, p = 0.052).

A Systematic Review Pooled 853 Records Down to 11 Small Trials

The authors searched PubMed, Google Scholar, Scopus, and ClinicalTrials.gov, turning up 853 candidate records that were narrowed down to eleven clinical trials meeting their criteria, spanning fecal transplants, the prebiotic fiber inulin, probiotic supplements, and neurohormonal drugs targeting ghrelin and GLP-1 receptors. Combined, those eleven trials enrolled 779 participants, with individual trial sizes ranging from just 16 to 151 people and average ages from 23.9 to 67.1 years; most trials were male-dominated except for one semaglutide trial that was 71 percent female. That size range is the central limitation of this evidence base: it is a synthesis of small, mostly single-site pilot and phase 1 or 2 trials, not one large definitive study.

What This Could Mean If You Are Managing Alcohol Use Disorder

None of these interventions is an approved, proven treatment for alcohol use disorder, and none should be sought out or requested from a doctor on the strength of this review alone. That said, the pattern worth discussing with a physician is the GLP-1 signal: of five trials of GLP-1 receptor agonists (the hormone-mimicking drug class that includes semaglutide, sold as Ozempic and Wegovy), three found statistically significant reductions in drinking. In one 48-person trial, once-weekly semaglutide reduced drinks per drinking day, weekly craving, and heavy drinking days compared with placebo. In a separate 108-person comparison of matched patients with AUD and comorbid obesity, weekly semaglutide (2.4 mg) was linked to a 41.1 percent reduction in heavy drinking days over 26 weeks versus a 26.4 percent reduction in the matched comparison group (p = 0.015). A third GLP-1 drug, dulaglutide, reduced weekly alcohol intake by 29 percent versus placebo after 12 weeks in a secondary analysis (p = 0.04), though that effect disappeared among the heaviest drinkers. But the picture is not uniform: an oral semaglutide trial missed its main goal of reducing lab-measured craving, even though it still reduced heavy drinking days and alcohol-related consequences on secondary measures, and a 127-person exenatide trial found no overall effect except in a subgroup of people with obesity. On the microbiome side, a probiotic containing Lactobacillus rhamnosus GG improved liver scores and drinking outcomes in people with alcohol-associated hepatitis, while inulin (a prebiotic fiber that feeds beneficial gut bacteria) raised a brain-supporting protein called BDNF and improved sociability without significantly cutting relapse.

Small Samples and Mixed Significance Are the Honest Limits Here

The caveats are substantial and worth naming plainly: individual trial sizes ranged from just 16 to 151 participants, several key results (including the FMT trial's 6-month abstinence finding and the inulin trial's relapse rate) did not reach statistical significance, and this paper is a systematic review of existing small studies rather than a single, adequately powered randomized trial. A ghrelin receptor antagonist drug tested in an 11-person trial produced no significant change in inflammatory markers at all, a reminder that not every gut-hormone target pans out. The review's authors are explicit that "large-scale, controlled trials are needed to validate and optimize" any of these approaches before they could become part of standard AUD care.

Larger Trials Are Already Underway

The clearest next step is already in motion for the GLP-1 angle: the VA-sponsored CRAVE trial is enrolling more than 600 U.S. veterans with moderate to severe AUD across 18 VA medical centers in a phase 3, placebo-controlled test of semaglutide, with results expected around 2029 to 2030. Microbiome-targeted approaches like FMT and probiotics have not yet reached that scale of trial, so their evidence base is likely to grow more slowly, through follow-up studies from the same small research groups rather than a single decisive trial.

Common Questions

Does Ozempic or Wegovy (semaglutide) treat alcohol use disorder? Semaglutide is not approved for alcohol use disorder. Early trials found it reduced heavy drinking days and craving in some studies, but the effect was not statistically significant in every trial, and a large veterans' trial is still years from reporting results.

Can a fecal transplant cure alcoholism? No. The trials reviewed here used FMT to reduce craving and short-term drinking-related complications in small groups of patients with alcohol-related liver disease, not to eliminate alcohol use disorder, and the improvement in long-term abstinence was not statistically significant.

What is the gut-brain axis? It is the two-way communication network between gut bacteria and the brain, carried out through the vagus nerve, immune signaling molecules, and hormones like GLP-1 and ghrelin that gut bacteria help regulate.

Are probiotics or prebiotic fiber helpful for alcohol use disorder? Early, small trials of a specific probiotic strain (Lactobacillus rhamnosus GG) and the prebiotic fiber inulin showed some benefits on liver markers, mood, and social functioning, but neither is an established or approved treatment for AUD.

References

1. Prabha Bhandari, Abdelhaleem Sideeg, Mohamed Elfeki, Chencheng Xie, Ashwani K. Singal (2026). Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review. Metabolism Open. https://doi.org/10.1016/j.metop.2026.100495
2. Jasmohan S. Bajaj, Edith A. Gavis, Andrew Fagan, et al. (2021). A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder. Hepatology. https://doi.org/10.1002/hep.31496
3. Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2024.4789
4. Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) Trial. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT07218354